GlassScriptPhysician profile
Joseph I Lee
NPI 1952497521
$32,071.73
in general payments reported to CMS, 2019-2025
45 companies · $7,633 in 2025
The $7,633 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,962 · 2020: $2,458 · 2021: $4,060 · 2022: $3,344 · 2023: $3,838 · 2024: $7,778 · 2025: $7,633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $7,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,573.02 |
| Consulting Fee | $7,675.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Uk Limited | $8,397.00 | 2021-2025 | |
| Boston Scientific Corporation | $3,758.51 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Accolade Sr |
| Abbott Laboratories | $2,326.56 | 2020-2025 | Pressurewire, Xience Skypoint, Nc Trek Neo |
| Novartis Pharmaceuticals Corporation | $2,253.06 | 2019-2025 | |
| Amgen INC. | $1,668.94 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $1,604.06 | 2019-2025 | Farxiga, Brilinta, Lokelma |
| Pfizer INC. | $1,188.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,126.91 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $1,110.06 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $935.81 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $847.74 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $845.99 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Janssen Pharmaceuticals, INC | $833.59 | 2019-2024 | Xarelto |
| Medtronic, INC. | $625.14 | 2021-2025 | Onyx Frontier, Micra, Linq II |
| Abiomed | $597.68 | 2022-2025 | Impella |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.